Cortisol in schizophrenia: No association with tobacco smoking, clinical symptoms or antipsychotic medication

Cigarette smoking is associated with higher cortisol levels in healthy subjects. In schizophrenia this relationship is not clear. There are divergent results on the association between cortisol with smoking, clinical symptoms and medication in schizophrenia. This study evaluated this association in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Progress in neuro-psychopharmacology & biological psychiatry 2017-07, Vol.77, p.228-235
Hauptverfasser: Nedic Erjavec, Gordana, Uzun, Suzana, Nikolac Perkovic, Matea, Kozumplik, Oliver, Svob Strac, Dubravka, Mimica, Ninoslav, Hirasawa-Fujita, Mika, Domino, Edward F., Pivac, Nela
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 235
container_issue
container_start_page 228
container_title Progress in neuro-psychopharmacology & biological psychiatry
container_volume 77
creator Nedic Erjavec, Gordana
Uzun, Suzana
Nikolac Perkovic, Matea
Kozumplik, Oliver
Svob Strac, Dubravka
Mimica, Ninoslav
Hirasawa-Fujita, Mika
Domino, Edward F.
Pivac, Nela
description Cigarette smoking is associated with higher cortisol levels in healthy subjects. In schizophrenia this relationship is not clear. There are divergent results on the association between cortisol with smoking, clinical symptoms and medication in schizophrenia. This study evaluated this association in 196 Caucasian inpatients with schizophrenia (51.30±26.68years old), subdivided into 123 smokers and 73 non-smokers. Basal salivary cortisol levels were measured twice, at 08.00 and 09.00AM, 90–120min after awakening. The effect of smoking on cortisol was evaluated according to current smoking status, the number of cigarettes/day and the nicotine addiction intensity. The influence of clinical symptoms and/or antipsychotic medication on cortisol was determined using the Positive and Negative Syndrome Scale (PANSS), and chlorpromazine equivalent doses. Non-smokers were older, received lower doses of antipsychotics, had higher PANSS scores, and had longer duration of illness than smokers. Salivary cortisol was similar in schizophrenic patients subdivided according to the smoking status, the number of cigarettes/day and nicotine addiction intensity. No significant correlation was found between salivary cortisol and PANSS scores, chlorpromazine equivalent doses, age of onset or the duration of illness. The findings revealed no association between salivary cortisol and smoking, nicotine addiction intensity, or clinical symptoms. Our preliminary data showed no correlation between salivary cortisol and chlorpromazine equivalent doses and/or antipsychotic medication. Our findings suggest that smoking does not affect the cortisol response in schizophrenic patients as it has been shown in healthy individuals. Future studies should investigate a possible desensitization of the stress system to smoking. •Saliva cortisol was not associated with smoking in schizophrenia.•Saliva cortisol did not differ after the first cigarette smoked that day in smokers.•Saliva cortisol was not related to the intensity of nicotine addiction in smokers.•Saliva cortisol was not correlated with various clinical symptoms of schizophrenia.•Saliva cortisol did not differ in patients treated with different antipsychotics.
doi_str_mv 10.1016/j.pnpbp.2017.04.032
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1894521068</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0278584616304675</els_id><sourcerecordid>1894521068</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-c1011da18fc698b4a09ad4c13a6014a2401272222f9445470d5ca1cd0bfc9a7c3</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi0EokvhFyBVPnJgw9hxvipxqFZ8SRVc2rPlTJzuLImd2l7Q8uvxdluOzMUj65kZvQ9jbwUUAkT9YVcsbumXQoJoClAFlPIZW4m2addKivo5W4HMfdWq-oy9inEHAKKE8iU7k_lPyEqu2LzxIVH0EyfHI27pj1-2wToyl_y75yZGj2QSecd_U9ry5HuD6Hmc_U9yd-85TuQIzcTjYV6SnyP3gRuXaIkH3PpEyGc7ZOK44zV7MZop2jeP7zm7_fzpZvN1ff3jy7fN1fUaFai0xpxPDEa0I9Zd2ysDnRkUitLUIJSRCoRsZK6xU6pSDQwVGoED9CN2psHynL077V2Cv9_bmPRMEe00GWf9PmrRdqqSAuo2o-UJxeBjDHbUS6DZhIMWoI-e9U4_eNZHzxqUzp7z1MXjgX2f4_2beRKbgY8nwOaYv8gGHZGsw6wiWEx68PTfA38Bxr2Rgg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1894521068</pqid></control><display><type>article</type><title>Cortisol in schizophrenia: No association with tobacco smoking, clinical symptoms or antipsychotic medication</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Nedic Erjavec, Gordana ; Uzun, Suzana ; Nikolac Perkovic, Matea ; Kozumplik, Oliver ; Svob Strac, Dubravka ; Mimica, Ninoslav ; Hirasawa-Fujita, Mika ; Domino, Edward F. ; Pivac, Nela</creator><creatorcontrib>Nedic Erjavec, Gordana ; Uzun, Suzana ; Nikolac Perkovic, Matea ; Kozumplik, Oliver ; Svob Strac, Dubravka ; Mimica, Ninoslav ; Hirasawa-Fujita, Mika ; Domino, Edward F. ; Pivac, Nela</creatorcontrib><description>Cigarette smoking is associated with higher cortisol levels in healthy subjects. In schizophrenia this relationship is not clear. There are divergent results on the association between cortisol with smoking, clinical symptoms and medication in schizophrenia. This study evaluated this association in 196 Caucasian inpatients with schizophrenia (51.30±26.68years old), subdivided into 123 smokers and 73 non-smokers. Basal salivary cortisol levels were measured twice, at 08.00 and 09.00AM, 90–120min after awakening. The effect of smoking on cortisol was evaluated according to current smoking status, the number of cigarettes/day and the nicotine addiction intensity. The influence of clinical symptoms and/or antipsychotic medication on cortisol was determined using the Positive and Negative Syndrome Scale (PANSS), and chlorpromazine equivalent doses. Non-smokers were older, received lower doses of antipsychotics, had higher PANSS scores, and had longer duration of illness than smokers. Salivary cortisol was similar in schizophrenic patients subdivided according to the smoking status, the number of cigarettes/day and nicotine addiction intensity. No significant correlation was found between salivary cortisol and PANSS scores, chlorpromazine equivalent doses, age of onset or the duration of illness. The findings revealed no association between salivary cortisol and smoking, nicotine addiction intensity, or clinical symptoms. Our preliminary data showed no correlation between salivary cortisol and chlorpromazine equivalent doses and/or antipsychotic medication. Our findings suggest that smoking does not affect the cortisol response in schizophrenic patients as it has been shown in healthy individuals. Future studies should investigate a possible desensitization of the stress system to smoking. •Saliva cortisol was not associated with smoking in schizophrenia.•Saliva cortisol did not differ after the first cigarette smoked that day in smokers.•Saliva cortisol was not related to the intensity of nicotine addiction in smokers.•Saliva cortisol was not correlated with various clinical symptoms of schizophrenia.•Saliva cortisol did not differ in patients treated with different antipsychotics.</description><identifier>ISSN: 0278-5846</identifier><identifier>EISSN: 1878-4216</identifier><identifier>DOI: 10.1016/j.pnpbp.2017.04.032</identifier><identifier>PMID: 28461252</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Adult ; Antipsychotic Agents - therapeutic use ; Antipsychotic medication ; Case-Control Studies ; Caucasians ; Chlorpromazine equivalent doses ; Cigarette smoking ; Female ; Humans ; Hydrocortisone - metabolism ; Male ; Middle Aged ; Nicotine addiction ; Saliva - metabolism ; Salivary cortisol ; Schizophrenia ; Schizophrenia - diagnosis ; Schizophrenia - drug therapy ; Schizophrenia - metabolism ; Schizophrenia symptoms ; Smoking - metabolism</subject><ispartof>Progress in neuro-psychopharmacology &amp; biological psychiatry, 2017-07, Vol.77, p.228-235</ispartof><rights>2017</rights><rights>Copyright © 2017. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-c1011da18fc698b4a09ad4c13a6014a2401272222f9445470d5ca1cd0bfc9a7c3</citedby><cites>FETCH-LOGICAL-c404t-c1011da18fc698b4a09ad4c13a6014a2401272222f9445470d5ca1cd0bfc9a7c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.pnpbp.2017.04.032$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28461252$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nedic Erjavec, Gordana</creatorcontrib><creatorcontrib>Uzun, Suzana</creatorcontrib><creatorcontrib>Nikolac Perkovic, Matea</creatorcontrib><creatorcontrib>Kozumplik, Oliver</creatorcontrib><creatorcontrib>Svob Strac, Dubravka</creatorcontrib><creatorcontrib>Mimica, Ninoslav</creatorcontrib><creatorcontrib>Hirasawa-Fujita, Mika</creatorcontrib><creatorcontrib>Domino, Edward F.</creatorcontrib><creatorcontrib>Pivac, Nela</creatorcontrib><title>Cortisol in schizophrenia: No association with tobacco smoking, clinical symptoms or antipsychotic medication</title><title>Progress in neuro-psychopharmacology &amp; biological psychiatry</title><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><description>Cigarette smoking is associated with higher cortisol levels in healthy subjects. In schizophrenia this relationship is not clear. There are divergent results on the association between cortisol with smoking, clinical symptoms and medication in schizophrenia. This study evaluated this association in 196 Caucasian inpatients with schizophrenia (51.30±26.68years old), subdivided into 123 smokers and 73 non-smokers. Basal salivary cortisol levels were measured twice, at 08.00 and 09.00AM, 90–120min after awakening. The effect of smoking on cortisol was evaluated according to current smoking status, the number of cigarettes/day and the nicotine addiction intensity. The influence of clinical symptoms and/or antipsychotic medication on cortisol was determined using the Positive and Negative Syndrome Scale (PANSS), and chlorpromazine equivalent doses. Non-smokers were older, received lower doses of antipsychotics, had higher PANSS scores, and had longer duration of illness than smokers. Salivary cortisol was similar in schizophrenic patients subdivided according to the smoking status, the number of cigarettes/day and nicotine addiction intensity. No significant correlation was found between salivary cortisol and PANSS scores, chlorpromazine equivalent doses, age of onset or the duration of illness. The findings revealed no association between salivary cortisol and smoking, nicotine addiction intensity, or clinical symptoms. Our preliminary data showed no correlation between salivary cortisol and chlorpromazine equivalent doses and/or antipsychotic medication. Our findings suggest that smoking does not affect the cortisol response in schizophrenic patients as it has been shown in healthy individuals. Future studies should investigate a possible desensitization of the stress system to smoking. •Saliva cortisol was not associated with smoking in schizophrenia.•Saliva cortisol did not differ after the first cigarette smoked that day in smokers.•Saliva cortisol was not related to the intensity of nicotine addiction in smokers.•Saliva cortisol was not correlated with various clinical symptoms of schizophrenia.•Saliva cortisol did not differ in patients treated with different antipsychotics.</description><subject>Adult</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotic medication</subject><subject>Case-Control Studies</subject><subject>Caucasians</subject><subject>Chlorpromazine equivalent doses</subject><subject>Cigarette smoking</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrocortisone - metabolism</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nicotine addiction</subject><subject>Saliva - metabolism</subject><subject>Salivary cortisol</subject><subject>Schizophrenia</subject><subject>Schizophrenia - diagnosis</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - metabolism</subject><subject>Schizophrenia symptoms</subject><subject>Smoking - metabolism</subject><issn>0278-5846</issn><issn>1878-4216</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAQhi0EokvhFyBVPnJgw9hxvipxqFZ8SRVc2rPlTJzuLImd2l7Q8uvxdluOzMUj65kZvQ9jbwUUAkT9YVcsbumXQoJoClAFlPIZW4m2addKivo5W4HMfdWq-oy9inEHAKKE8iU7k_lPyEqu2LzxIVH0EyfHI27pj1-2wToyl_y75yZGj2QSecd_U9ry5HuD6Hmc_U9yd-85TuQIzcTjYV6SnyP3gRuXaIkH3PpEyGc7ZOK44zV7MZop2jeP7zm7_fzpZvN1ff3jy7fN1fUaFai0xpxPDEa0I9Zd2ysDnRkUitLUIJSRCoRsZK6xU6pSDQwVGoED9CN2psHynL077V2Cv9_bmPRMEe00GWf9PmrRdqqSAuo2o-UJxeBjDHbUS6DZhIMWoI-e9U4_eNZHzxqUzp7z1MXjgX2f4_2beRKbgY8nwOaYv8gGHZGsw6wiWEx68PTfA38Bxr2Rgg</recordid><startdate>20170703</startdate><enddate>20170703</enddate><creator>Nedic Erjavec, Gordana</creator><creator>Uzun, Suzana</creator><creator>Nikolac Perkovic, Matea</creator><creator>Kozumplik, Oliver</creator><creator>Svob Strac, Dubravka</creator><creator>Mimica, Ninoslav</creator><creator>Hirasawa-Fujita, Mika</creator><creator>Domino, Edward F.</creator><creator>Pivac, Nela</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170703</creationdate><title>Cortisol in schizophrenia: No association with tobacco smoking, clinical symptoms or antipsychotic medication</title><author>Nedic Erjavec, Gordana ; Uzun, Suzana ; Nikolac Perkovic, Matea ; Kozumplik, Oliver ; Svob Strac, Dubravka ; Mimica, Ninoslav ; Hirasawa-Fujita, Mika ; Domino, Edward F. ; Pivac, Nela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-c1011da18fc698b4a09ad4c13a6014a2401272222f9445470d5ca1cd0bfc9a7c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotic medication</topic><topic>Case-Control Studies</topic><topic>Caucasians</topic><topic>Chlorpromazine equivalent doses</topic><topic>Cigarette smoking</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrocortisone - metabolism</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nicotine addiction</topic><topic>Saliva - metabolism</topic><topic>Salivary cortisol</topic><topic>Schizophrenia</topic><topic>Schizophrenia - diagnosis</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - metabolism</topic><topic>Schizophrenia symptoms</topic><topic>Smoking - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nedic Erjavec, Gordana</creatorcontrib><creatorcontrib>Uzun, Suzana</creatorcontrib><creatorcontrib>Nikolac Perkovic, Matea</creatorcontrib><creatorcontrib>Kozumplik, Oliver</creatorcontrib><creatorcontrib>Svob Strac, Dubravka</creatorcontrib><creatorcontrib>Mimica, Ninoslav</creatorcontrib><creatorcontrib>Hirasawa-Fujita, Mika</creatorcontrib><creatorcontrib>Domino, Edward F.</creatorcontrib><creatorcontrib>Pivac, Nela</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Progress in neuro-psychopharmacology &amp; biological psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nedic Erjavec, Gordana</au><au>Uzun, Suzana</au><au>Nikolac Perkovic, Matea</au><au>Kozumplik, Oliver</au><au>Svob Strac, Dubravka</au><au>Mimica, Ninoslav</au><au>Hirasawa-Fujita, Mika</au><au>Domino, Edward F.</au><au>Pivac, Nela</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cortisol in schizophrenia: No association with tobacco smoking, clinical symptoms or antipsychotic medication</atitle><jtitle>Progress in neuro-psychopharmacology &amp; biological psychiatry</jtitle><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><date>2017-07-03</date><risdate>2017</risdate><volume>77</volume><spage>228</spage><epage>235</epage><pages>228-235</pages><issn>0278-5846</issn><eissn>1878-4216</eissn><abstract>Cigarette smoking is associated with higher cortisol levels in healthy subjects. In schizophrenia this relationship is not clear. There are divergent results on the association between cortisol with smoking, clinical symptoms and medication in schizophrenia. This study evaluated this association in 196 Caucasian inpatients with schizophrenia (51.30±26.68years old), subdivided into 123 smokers and 73 non-smokers. Basal salivary cortisol levels were measured twice, at 08.00 and 09.00AM, 90–120min after awakening. The effect of smoking on cortisol was evaluated according to current smoking status, the number of cigarettes/day and the nicotine addiction intensity. The influence of clinical symptoms and/or antipsychotic medication on cortisol was determined using the Positive and Negative Syndrome Scale (PANSS), and chlorpromazine equivalent doses. Non-smokers were older, received lower doses of antipsychotics, had higher PANSS scores, and had longer duration of illness than smokers. Salivary cortisol was similar in schizophrenic patients subdivided according to the smoking status, the number of cigarettes/day and nicotine addiction intensity. No significant correlation was found between salivary cortisol and PANSS scores, chlorpromazine equivalent doses, age of onset or the duration of illness. The findings revealed no association between salivary cortisol and smoking, nicotine addiction intensity, or clinical symptoms. Our preliminary data showed no correlation between salivary cortisol and chlorpromazine equivalent doses and/or antipsychotic medication. Our findings suggest that smoking does not affect the cortisol response in schizophrenic patients as it has been shown in healthy individuals. Future studies should investigate a possible desensitization of the stress system to smoking. •Saliva cortisol was not associated with smoking in schizophrenia.•Saliva cortisol did not differ after the first cigarette smoked that day in smokers.•Saliva cortisol was not related to the intensity of nicotine addiction in smokers.•Saliva cortisol was not correlated with various clinical symptoms of schizophrenia.•Saliva cortisol did not differ in patients treated with different antipsychotics.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>28461252</pmid><doi>10.1016/j.pnpbp.2017.04.032</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0278-5846
ispartof Progress in neuro-psychopharmacology & biological psychiatry, 2017-07, Vol.77, p.228-235
issn 0278-5846
1878-4216
language eng
recordid cdi_proquest_miscellaneous_1894521068
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Adult
Antipsychotic Agents - therapeutic use
Antipsychotic medication
Case-Control Studies
Caucasians
Chlorpromazine equivalent doses
Cigarette smoking
Female
Humans
Hydrocortisone - metabolism
Male
Middle Aged
Nicotine addiction
Saliva - metabolism
Salivary cortisol
Schizophrenia
Schizophrenia - diagnosis
Schizophrenia - drug therapy
Schizophrenia - metabolism
Schizophrenia symptoms
Smoking - metabolism
title Cortisol in schizophrenia: No association with tobacco smoking, clinical symptoms or antipsychotic medication
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T19%3A58%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cortisol%20in%20schizophrenia:%20No%20association%20with%20tobacco%20smoking,%20clinical%20symptoms%20or%20antipsychotic%20medication&rft.jtitle=Progress%20in%20neuro-psychopharmacology%20&%20biological%20psychiatry&rft.au=Nedic%20Erjavec,%20Gordana&rft.date=2017-07-03&rft.volume=77&rft.spage=228&rft.epage=235&rft.pages=228-235&rft.issn=0278-5846&rft.eissn=1878-4216&rft_id=info:doi/10.1016/j.pnpbp.2017.04.032&rft_dat=%3Cproquest_cross%3E1894521068%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1894521068&rft_id=info:pmid/28461252&rft_els_id=S0278584616304675&rfr_iscdi=true